


AMENDMENTS TO THE CLAIMS

1. (Original) A compound represented by the formula (I):



wherein R⁷ and R²¹, the same or different, represent

- 1) a C₂ to C₂₂ alkoxy group which may have a substituent,
- 2) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
- 3) a C₇ to C₂₂ aralkyloxy group which may have a substituent,
- 4) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,
- 5) RC(=Y)-O-, wherein Y represents an oxygen atom or sulfur atom, and R represents
 - a) a hydrogen atom,
 - b) a C₂ to C₂₂ alkyl group which may have a substituent,
 - c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - d) a C₆ to C₁₄ aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C₇ to C₂₂ aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - h) a C₁ to C₂₂ alkoxy group which may have a substituent,

- i) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
- j) a C₆ to C₁₄ aryloxy group which may have a substituent,
- k) a C₃ to C₁₄ cycloalkyl group which may have a substituent,
- l) a 3-membered to 14-membered non-aromatic heterocyclic group which may

have a substituent or

m) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

6) R^{S1}R^{S2}R^{S3}SiO-, wherein R^{S1}, R^{S2} and R^{S3}, the same or different, represent

a) a C₁ to C₆ alkyl group or

b) a C₆ to C₁₄ aryl group,

7) a halogen atom,

8) R^{N1}R^{N2}N-R^M-, wherein R^M represents

a) a single bond,

b) -CO-O-,

c) -SO₂-O-,

d) -CS-O- or

e) -CO-NR^{N3}-, wherein R^{N3} represents a hydrogen atom or a C₁ to C₆ alkyl group

which may have a substituent, provided that, the leftmost bond in b) to e) is bonded to the nitrogen atom, and

R^{N1} and R^{N2}, the same or different, represent

a) a hydrogen atom,

b) a C₁ to C₂₂ alkyl group which may have a substituent,

- c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
 - d) an aliphatic C₂ to C₂₂ acyl group which may have a substituent,
 - e) an aromatic C₇ to C₁₅ acyl group which may have a substituent,
 - f) a C₆ to C₁₄ aryl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - h) a C₇ to C₂₂ aralkyl group which may have a substituent,
 - i) a C₁ to C₂₂ alkylsulfonyl group which may have a substituent,
 - j) a C₆ to C₁₄ arylsulfonyl group which may have a substituent,
 - k) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{N1} and R^{N2} together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,
 - l) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - m) a C₃ to C₁₄ cycloalkyl group which may have a substituent or
 - n) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- 9) R^{N4}SO₂-O-, wherein R^{N4} represents
- a) a C₁ to C₂₂ alkyl group which may have a substituent,
 - b) a C₆ to C₁₄ aryl group which may have a substituent,
 - c) a C₁ to C₂₂ alkoxy group which may have a substituent,
 - d) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,

e) a C₆ to C₁₄ aryloxy group which may have a substituent,

f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,

g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or

h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

10) (R^{N5}O)₂PO-O-, wherein R^{N5} represents

a) a C₁ to C₂₂ alkyl group which may have a substituent,

b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

c) a C₆ to C₁₄ aryl group which may have a substituent,

d) a 5-membered to 14-membered heteroaryl group which may have a substituent,


e) a C₇ to C₂₂ aralkyl group which may have a substituent or

f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

11) (R^{N1}R^{N2}N)₂PO-O-, wherein R^{N1} and R^{N2} are the same as defined above or

12) (R^{N1}R^{N2}N)(R^{N5}O)PO-O-, wherein R^{N1}, R^{N2} and R^{N5} are the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

2. (Original) The compound according to claim 1 represented by the formula (I-a):



wherein R^{7a} and R^{21a} , the same or different, represent

- 1) a C_2 to C_{22} alkoxy group which may have a substituent,
- 2) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,
- 3) a C_7 to C_{22} aralkyloxy group which may have a substituent,
- 4) $R^aC(=Y^a)-O-$, wherein Y^a represents an oxygen atom or sulfur atom, and R^a represents
 - a) a hydrogen atom,
 - b) a C_2 to C_{22} alkyl group which may have a substituent,
 - c) an unsaturated C_2 to C_{22} alkyl group which may have a substituent,
 - d) a C_6 to C_{14} aryl group which may have a substituent,
 - e) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - f) a C_7 to C_{22} aralkyl group which may have a substituent,
 - g) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - h) a C_1 to C_{22} alkoxy group which may have a substituent,
 - i) an unsaturated C_2 to C_{22} alkoxy group which may have a substituent,

j) a C₆ to C₁₄ aryloxy group which may have a substituent or

k) a 3-membered to 14-membered heteroaryloxy group which may have a substituent,

5) R^{aN1}R^{aN2}N-CO-O-, wherein R^{aN1} and R^{aN2}, the same or different, represent

a) a hydrogen atom,

b) a C₁ to C₂₂ alkyl group which may have a substituent,

c) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,

d) a C₆ to C₁₄ aryl group which may have a substituent,

e) a 5-membered to 14-membered heteroaryl group which may have a substituent,

f) a C₇ to C₂₂ aralkyl group which may have a substituent,

g) a 3-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN1} and R^{aN2} together in combination with the nitrogen atom to which R^{aN1} and R^{aN2} are bonded, wherein the 3-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

h) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

i) a C₃ to C₁₄ cycloalkyl group which may have a substituent or

j) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

6) R^{aN1}R^{aN2}N-SO₂-O-, wherein R^{aN1} and R^{aN2} are the same as defined above,

7) R^{aN1}R^{aN2}N-CS-O-, wherein R^{aN1} and R^{aN2} are the same as defined above,

8) R^{aN4}SO₂-O-, wherein R^{aN4} represents

- a) a C₁ to C₂₂ alkyl group which may have a substituent,
- b) a C₆ to C₁₄ aryl group which may have a substituent,
- c) a C₁ to C₂₂ alkoxy group which may have a substituent,
- d) an unsaturated C₂ to C₂₂ alkoxy group which may have a substituent,
- e) a C₆ to C₁₄ aryloxy group which may have a substituent,
- f) a 5-membered to 14-membered heteroaryloxy group which may have a substituent,
- g) a C₇ to C₂₂ aralkyloxy group which may have a substituent or
- h) a 5-membered to 14-membered heteroaralkyloxy group which may have a substituent,

9) (R^{aN5}O)₂PO-O-, wherein R^{aN5} represents

- a) a C₁ to C₂₂ alkyl group which may have a substituent,
- b) an unsaturated C₂ to C₂₂ alkyl group which may have a substituent,
- c) a C₆ to C₁₄ aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a C₇ to C₂₂ aralkyl group which may have a substituent or
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) (R^{aN1}R^{aN2}N)₂-PO-O-, wherein R^{aN1} and R^{aN2} are the same as defined above or


11) (R^{aN1}R^{aN2}N)(R^{aN5}O)PO-O-, wherein R^{aN1}, R^{aN2} and R^{aN5} are the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

3. (Original) The compound according to claim 1, wherein R^7 and/or R^{21} represent a C_7 to C_{22} aralkyloxy group which may have a substituent, $RC(=Y)-O-$, wherein Y and R are the same as defined above or $R^{N1}R^{N2}N-R^M-$, wherein R^M represents

a) $-CO-O-$ or


b) $-CS-O-$, and R^{N1} and R^{N2} are the same as defined above, provided that, the leftmost bond in a) and b) is bonded to the nitrogen atom; or a pharmacologically acceptable salt thereof, or a hydrate of those.

4. (Original) The compound according to claim 1, wherein R^{N1} and R^{N2} , the same or different, represent a C_1 to C_6 alkyl group or C_6 to C_{14} aryl group, or form, together in combination with the nitrogen atom to which R^{N1} and R^{N2} are bonded, a non-aromatic heterocyclic group selected from the group consisting of:




or a pharmacologically acceptable salt thereof, or a hydrate of those.

5. (Original) The compound according to claim 2 represented by the formula (I-b):



wherein R^{7b} and R^{21b} , the same or different, represent a C_7 to C_{22} aralkyloxy group which may have a substituent, or $R^b-C(=Y^b)-O-$, wherein Y^b represents an oxygen atom or sulfur atom, and R^b , the same or different, represents

- a) a hydrogen atom,
- b) a C_2 to C_6 alkyl group which may have a substituent,
- c) a C_6 to C_{14} aryl group which may have a substituent,
- d) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- e) a C_7 to C_{10} aralkyl group which may have a substituent,
- f) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- g) a 3-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- h) a group of the formula (III):



wherein A) n represents an integer of 0 to 4,

X_b represents

i) $-\text{CHR}^{bN4}-$,

ii) $-\text{NR}^{bN5}-$,

iii) $-\text{O}-$,

iv) $-\text{S}-$,

v) $-\text{SO}-$ or

vi) $-\text{SO}_2-$,

R^{bN1} represents

i) a hydrogen atom or

ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{bN2} represents

i) a hydrogen atom or

ii) a C_1 to C_6 alkyl group which may have a substituent,

R^{bN3} and R^{bN4} , the same or different, represent

i) a hydrogen atom,

ii) a C_1 to C_6 alkyl group which may have a substituent,

iii) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,

iv) a C_6 to C_{14} aryl group which may have a substituent,

- v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- vi) a C₇ to C₁₀ aralkyl group which may have a substituent,
- vii) a C₃ to C₈ cycloalkyl group which may have a substituent,
- viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
- x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
- xi) -NR^{bN6}R^{bN7}, wherein R^{bN6} and R^{bN7}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or
- xii) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN3} and R^{bN4} together in combination with the carbon atom to which R^{bN3} and R^{bN4} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and R^{bN5} represents
 - i) a hydrogen atom,
 - ii) a C₁ to C₆ alkyl group which may have a substituent,
 - iii) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
 - iv) a C₆ to C₁₄ aryl group which may have a substituent,
 - v) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - vi) a C₇ to C₁₀ aralkyl group which may have a substituent,
 - vii) a C₃ to C₈ cycloalkyl group which may have a substituent,

viii) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

ix) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

x) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent or

xi) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN3} and R^{bN5} together in combination with the nitrogen atom to which R^{bN3} and R^{bN5} are bonded, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

B)

X_b, n, R^{bN3}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN1} and R^{bN2} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN1} and R^{bN2} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent,

C)


X_b, n, R^{bN2}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN1} and R^{bN3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{bN1} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

D)

X_b, n, R^{bN1}, R^{bN4} and R^{bN5} represent the same group as defined above, and R^{bN2} and R^{bN3} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by

R^{bN2} and R^{bN3} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or

i) a group of the formula (IV):



wherein R^{bN8} and R^{bN9} , the same or different, represent


- i) a hydrogen atom,
- ii) a C_1 to C_6 alkyl group which may have a substituent,
- iii) a C_6 to C_{14} aryl group which may have a substituent,
- iv) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- v) a C_7 to C_{10} aralkyl group which may have a substituent or
- vi) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

6. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a1}C(=Y^{a1})-$ O-, wherein Y^{a1} represents an oxygen atom or sulfur atom, and R^{a1} represents

- 1) a hydrogen atom,
- 2) a C_2 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{10} aryl group which may have a substituent,

- 4) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 5) a C₇ to C₁₀ aralkyl group which may have a substituent or
- 6) a 5-membered to 14-membered heteroaralkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

7. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a2}C(=Y^{a2})-O-, wherein Y^{a2} represents an oxygen atom or sulfur atom, and R^{a2} represents a group of the formula (III'):



wherein A) n represents an integer of 0 to 4,

X₁ represents

- 1) -CHR^{aN9}-,
- 2) -NR^{aN10}-,
- 3) -O-,
- 4) -S-,
- 5) -SO- or
- 6) -SO₂-,

R^{aN6} and R^{aN7}, the same or different, represent

- 1) a hydrogen atom or

2) a C₁ to C₆ alkyl group which may have a substituent,

R^{aN8} and R^{aN9}, the same or different, represent

1) a hydrogen atom,

2) a C₁ to C₆ alkyl group which may have a substituent,

3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,

4) a C₆ to C₁₄ aryl group which may have a substituent,

5) a 5-membered to 14-membered heteroaryl group which may have a substituent,

6) a C₇ to C₁₀ aralkyl group which may have a substituent,

7) a C₃ to C₈ cycloalkyl group which may have a substituent,

8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,

11) -NR^{aN11}R^{aN12}, wherein R^{aN11} and R^{aN12}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN8} and R^{aN9} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent, and

R^{aN10} represents


1) a hydrogen atom,

2) a C₁ to C₆ alkyl group which may have a substituent,

- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
 - 4) a C₆ to C₁₄ aryl group which may have a substituent,
 - 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
 - 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
 - 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
 - 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
 - 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,
 - 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent,
 - 11) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{aN10} is bonded, and one substituent selected from the group consisting of R^{aN6}, R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or
 - 12) a 5-membered to 14-membered non-aromatic heterocyclic group formed by the nitrogen atom to which R^{aN10} is bonded, and two substituents selected from the group consisting of R^{aN6}, R^{aN7} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent or
- B) n, X₁, R^{aN7}, R^{aN9} and R^{aN10} represent the same group as defined above, and R^{aN6} and R^{aN8} represent a 5-membered to 14-membered non-aromatic heterocyclic group formed by R^{aN6} and R^{aN8} together, wherein the 5-membered to 14-membered non-aromatic heterocyclic group may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

8. (Original) The compound according to claim 6, wherein X_1 represents $-NR^{aN10}-$, wherein NR^{aN10} is the same as defined above; or a pharmacologically acceptable salt thereof, or a hydrate of those.

9. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a3}C(=Y^{a3})-$ O-, wherein Y^{a3} represents an oxygen atom or sulfur atom, and R^{a3} represents a group of the formula (V):



wherein n represents an integer of 0 to 4,

R^{aN13} represents

- 1) a hydrogen atom or
- 2) a C_1 to C_6 alkyl group which may have a substituent, and


R^{aN14} represents

- 1) a hydrogen atom,
- 2) an amino group which may have a substituent,
- 3) a pyridinyl group which may have a substituent,
- 4) a pyrrolidin-1-yl group which may have a substituent,
- 5) a piperidin-1-yl group which may have a substituent,

6) a morpholin-4-yl group which may have a substituent or

7) a piperazin-1-yl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

10. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a4}CO-O-$, wherein R^{a4} represents a group of the formula (VI):



wherein n_1 and n_2 , the same or different, represent an integer of 0 to 4,

X_2 represents

1) $-CHR^{aN17}-$,

2) $-NR^{aN18}-$,

3) $-O-$,

4) $-S-$,

5) $-SO-$ or

6) $-SO_2-$,

R^{aN15} represents

1) a hydrogen atom or

2) a C_1 to C_6 alkyl group which may have a substituent,

R^{aN16} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) a C₆ to C₁₄ aryl group which may have a substituent or
- 4) a C₇ to C₁₀ aralkyl group which may have a substituent,

R^{aN17} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent,

10) -NR^{aN19}R^{aN20}, wherein R^{aN19} and R^{aN20}, the same or different, represent a hydrogen atom or a C₁ to C₆ alkyl group which may have a substituent or


11) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{aN18} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,

- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

11. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a5}CO-O-, wherein R^{a5} represents a group of the formula (VII):



wherein n₃ represents 1 or 2,

R^{aN21} represents


- 1) a hydrogen atom or
- 2) a C₁ to C₆ alkyl group which may have a substituent, and

R^{aN22} represents

1) a hydrogen atom or

2) a C₁ to C₆ alkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

12. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a6}CO-O-, wherein R^{a6} represents a group of the formula (VIII):



wherein n₁ and n₂, the same or different, represent an integer of 0 to 4,

X₃ represents

1) -CHR^{aN25}-,

2) -NR^{aN26}-,

3) -O-,

4) -S-,

5) -SO- or

6) -SO₂-,

R^{aN23} represents

1) a hydrogen atom or

2) a C₁ to C₆ alkyl group which may have a substituent,

R^{aN24} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent,

R^{aN25} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_1 to C_6 alkoxy group which may have a substituent,
- 5) a C_6 to C_{14} aryl group which may have a substituent,
- 6) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 7) a C_7 to C_{10} aralkyl group which may have a substituent,
- 8) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 9) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,
- 10) a 5-membered to 14-membered heteroaralkyl group which may have a

substituent,


11) $-NR^{aN27}R^{aN28}$, wherein R^{aN27} and R^{aN28} , the same or different, represent a hydrogen atom or a C_1 to C_6 alkyl group which may have a substituent or

12) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent, and

R^{aN26} represents

- 1) a hydrogen atom,
- 2) a C₁ to C₆ alkyl group which may have a substituent,
- 3) an unsaturated C₂ to C₁₀ alkyl group which may have a substituent,
- 4) a C₆ to C₁₄ aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C₇ to C₁₀ aralkyl group which may have a substituent,
- 7) a C₃ to C₈ cycloalkyl group which may have a substituent,
- 8) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,
- 9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or
- 10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

13. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a7}CO-O-, wherein R^{a7} represents a group of the formula (IX):




wherein n₄ represents an integer of 1 to 3, and

R^{aN29} represents

- 1) an amino group which may have a substituent,

2) a pyrrolidin-1-yl group which may have a substituent,
 3) a piperidin-1-yl group which may have a substituent or
 4) a morpholin-4-yl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

14. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a8}CO-O-$, wherein R^{a8} represents a group of the formula (X):



wherein n_4 represents an integer of 1 to 3,

R^{aN30} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_6 to C_{14} aryl group which may have a substituent or
- 4) a C_7 to C_{10} aralkyl group which may have a substituent, and

R^{aN31} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 4) a 3-membered to 8-membered non-aromatic heterocyclic group which may

have a substituent,

5) a C₆ to C₁₄ aryl group which may have a substituent,


6) a 5-membered to 14-membered heteroaryl group which may have a substituent,

7) a C₇ to C₁₀ aralkyl group which may have a substituent,

8) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or

9) a C₄ to C₉ cycloalkylalkyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

15. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent R^{a9}CO-O-, wherein R^{a9} represents a group of the formula (XI):



wherein n₄ represents an integer of 1 to 3, and

R^{aN32} represents

1) a hydrogen atom,

2) a C₁ to C₆ alkyl group which may have a substituent,

3) a C₃ to C₈ cycloalkyl group which may have a substituent,


4) a C₄ to C₉ cycloalkylalkyl group which may have a substituent,

5) a C₇ to C₁₀ aralkyl group which may have a substituent,

6) a pyridyl group which may have a substituent or

7) a tetrahydropyranyl group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

16. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a10}CO-O-$, wherein R^{a10} represents a group of the formula (XII):



wherein m_1 , m_2 , m_3 and m_4 , the same or differently, represent 0 or 1,

n_4 represents an integer of 1 to 3, and


R^{aN33} represents

- 1) a hydrogen atom,
- 2) a C_1 to C_6 alkyl group which may have a substituent,
- 3) an unsaturated C_2 to C_{10} alkyl group which may have a substituent,
- 4) a C_6 to C_{14} aryl group which may have a substituent,
- 5) a 5-membered to 14-membered heteroaryl group which may have a substituent,
- 6) a C_7 to C_{10} aralkyl group which may have a substituent,
- 7) a C_3 to C_8 cycloalkyl group which may have a substituent,
- 8) a C_4 to C_9 cycloalkylalkyl group which may have a substituent,

9) a 5-membered to 14-membered heteroaralkyl group which may have a substituent or


10) a 5-membered to 14-membered non-aromatic heterocyclic group which may have a substituent; or a pharmacologically acceptable salt thereof, or a hydrate of those.

17. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a11}CO-O-$, wherein R^{a11} represents a group of the formula (XIII):




wherein m_5 represents an integer of 1 to 3, and n_5 represents 2 or 3; or a pharmacologically acceptable salt thereof, or a hydrate of those.

18. (Original) The compound according to claim 2, wherein R^{7a} and/or R^{21a} represent $R^{a12}CO-O-$, wherein R^{a12} represents a group selected from a group consisting of:



or a group selected from a group consisting of



and both of which may have a substituent on the ring;

or a pharmacologically acceptable salt thereof, or a hydrate of those.

19. (Original) The compound according to claim 1, which is (8E,12E,14E)-21-benzoyloxy-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide,

(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-21-N,N-dimethylcarbamoyloxy-7-((4-methylpiperazin-1-yl)carbonyl)oxy-18,19-epoxytricoso-8,12,14-trien-11-olide and

(8E,12E,14E)-3,6-dihydroxy-6,10,12,16,20-pentamethyl-7-((4-methylpiperazin-1-yl)carbonyl)oxy-21-phenylcarbamoyloxy-18,19-epoxytricoso-8,12,14-trien-11-olide; or a pharmacologically acceptable salt thereof, or a hydrate of those.

20. (Currently Amended) A medicine comprising the compound according to ~~any one of claims 1 to 19~~ claim 1, or a pharmacologically acceptable salt thereof, or a hydrate of those as an active ingredient.

21. (Currently Amended) A pharmaceutical composition comprising the compound according to ~~any one of claims 1 to 19~~ claim 1, or a pharmacologically acceptable salt thereof, or a hydrate of those as an active ingredient.

22. (Original) The medicine according to claim 20 as an agent for preventing or treating a disease for which gene expression control is effective.

23. (Original) The medicine according to claim 20 as an agent for preventing or treating a disease for which suppression of VEGF production is effective.

24. (Original) The medicine according to claim 20 as an agent for preventing or treating a disease for which an antiangiogenic effect is effective.

25. (Original) The medicine according to claim 20 as an angiogenesis inhibitor.

26. (Original) The medicine according to claim 20 as an antitumor agent.

27. (Original) The medicine according to claim 20 as a therapeutic agent for treating hemangioma.

28. (Original) The medicine according to claim 20 as a cancer metastasis inhibitor.

29. (Original) The medicine according to claim 20 as a therapeutic agent for treating retinal neovascularization or diabetic retinopathy.

30. (Original) The medicine according to claim 20 as a therapeutic agent for treating inflammatory disease.

31. (Original) The medicine according to claim 20 as a therapeutic agent for treating inflammatory diseases consisting of deformed arthritis, rheumatoid arthritis, psoriasis and delayed hypersensitive reaction.

32. (Original) The medicine according to claim 20 as a therapeutic agent for treating atherosclerosis.

33. (Original) The medicine according to claim 20 as a therapeutic agent for treating a solid cancer.

34. (Original) The medicine according to claim 33, wherein the solid cancer is lung cancer, brain tumor, breast cancer, prostate cancer, ovarian cancer, colon cancer or melanoma.

35. (Original) The medicine according to claim 20 as a therapeutic agent for treating leukemia.

36. (Original) The medicine according to claim 20 as an antitumor agent based on gene expression control.

37. (Original) The medicine according to claim 20 as an antitumor agent based on suppression of VEGF production.

38. (Original) The medicine according to claim 20 as an antitumor agent based on an effect of angiogenesis inhibition.

39. (Original) A method for preventing or treating a disease for which gene expression control is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.

40. (Original) A method for preventing or treating a disease for which suppression of VEGF production is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.

41. (Original) A method for preventing or treating a disease for which angiogenesis inhibition is effective, comprising administering a pharmacologically effective dose of the medicine according to claim 20 to a patient.

42. (Currently Amended) Use of the compound according to ~~any one of claims 1 to 19~~ claim 1, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which gene expression control is effective.

43. (Currently Amended) Use of the compound according to ~~any one of claims 1 to 19~~ claim 1, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which suppression of VEGF production inhibition is effective.

44. (Currently Amended) Use of the compound according to ~~any one of claims 1 to 19~~ claim 1, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a disease for which angiogenesis inhibition is effective.

45. (Currently Amended) Use of the compound according to ~~any one of claims 1 to 19~~ claim 1, or a pharmacologically acceptable salt thereof or a hydrate of those, for manufacturing an agent for preventing or treating a solid cancer.